Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Novel concepts in androgen receptor blockade.

Hsieh AC, Ryan CJ.

Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e. Review.

PMID:
18303477
2.

Novel secondary hormonal therapy in advanced prostate cancer: an update.

Van Allen EM, Ryan CJ.

Curr Opin Urol. 2009 May;19(3):315-21. doi: 10.1097/MOU.0b013e328329b73a. Review.

PMID:
19342958
3.

Innovative approaches to the hormonal treatment of advanced prostate cancer.

Trachtenberg J.

Eur Urol. 1997;32 Suppl 3:78-80. Review.

PMID:
9267790
4.

Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.

Vis AN, Schröder FH.

BJU Int. 2009 Nov;104(9):1191-7. doi: 10.1111/j.1464-410X.2009.08743.x. Epub 2009 Jul 14. Review.

5.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
6.

Secondary hormonal manipulations in prostate cancer.

Ryan CJ.

Hematol Oncol Clin North Am. 2006 Aug;20(4):925-34. Review.

PMID:
16861123
7.

Combinatorial androgen receptor targeted therapy for prostate cancer.

Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT.

Endocr Relat Cancer. 2006 Sep;13(3):653-66. Review.

8.

Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.

Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.

Am J Ther. 2010 Mar-Apr;17(2):176-81. doi: 10.1097/MJT.0b013e3181c6c0b2. Review.

PMID:
20019584
9.

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Taplin ME.

Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. Review.

PMID:
17392714
10.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

11.

Novel hormonal approaches in prostate cancer.

Friedlander TW, Ryan CJ.

Curr Oncol Rep. 2009 May;11(3):227-34. Review.

PMID:
19336015
12.

Overview of enzyme inhibitors and anti-androgens in prostatic cancer.

Geller J.

J Androl. 1991 Nov-Dec;12(6):364-71. Review.

13.

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Rittmaster RS.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016. Review.

PMID:
18471794
14.

Intra-prostatic androgen levels during various androgen-blockade regimens.

Nishiyama T.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):229-41. doi: 10.1016/j.beem.2008.01.002. Review.

PMID:
18471782
15.

[Hormonal therapy for benign prostatic hyperplasia].

Sakai H, Kanetake H.

Nihon Rinsho. 2002 Dec;60 Suppl 11:358-61. Review. Japanese. No abstract available.

PMID:
12599600
16.

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

Molina A, Belldegrun A.

J Urol. 2011 Mar;185(3):787-94. doi: 10.1016/j.juro.2010.10.042. Epub 2011 Jan 15. Review. Erratum in: J Urol. 2011 Aug;186(2):762.

PMID:
21239012
17.

P450-dependent enzymes as targets for prostate cancer therapy.

De Coster R, Wouters W, Bruynseels J.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):133-43. Review.

PMID:
8603034
18.

5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

Dörsam J, Altwein J.

Prostate Cancer Prostatic Dis. 2009;12(2):130-6. doi: 10.1038/pcan.2008.56. Epub 2008 Nov 25. Review.

PMID:
19030020
19.

Secondary hormonal manipulations in prostate cancer.

Ryan CJ, Small EJ.

Curr Oncol Rep. 2005 May;7(3):228-33. Review.

PMID:
15847715
20.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832

Supplemental Content

Support Center